#### LTACH Collaborative and vSNF Workgroup Joint Meeting

Antimicrobial Prescribing and Transitions of Care Communication

June 14, 2023

Healthcare-Associated Infections Program
Center for Health Care Quality
California Department of Public Health



#### **Housekeeping Reminders**



This session is being recorded



If your name does not show up, please "right click" to rename



Please stay muted if you are not speaking



To comment, you can unmute or type into the Chat



#### **Agenda**

12-12:05PM	Welcome
12:05-12:35PM	Interfacility Transfer Communication and Transitions of Care in Antimicrobial Stewardship
12:35-1:05PM	<ul> <li>Guest Speakers on Transitions of Care</li> <li>Grace Hassid, San Mateo Medical Center</li> <li>Philip Robinson and Jason Yamaki, Hoag Hospital</li> </ul>
1:05-1:25PM	Group Discussion
1:25-1:30PM	Next Steps



#### **Implicit Bias**

- Describes how our unconscious attitudes or judgements can influence our thoughts, decisions, or actions
- Includes involuntary, unintentional perceptions made without awareness
- Occurs as our brains sort information and perceive data to understand our world
- Affects our decisions, contributing to societal disparities
  - Self awareness about implicit bias can promote healthcare diversity and equality
- Learn more about your own implicit bias at <u>Project</u>
   <u>Implicit</u> (implicit.harvard.edu/implicit/)





## INTERFACILITY TRANSFER COMMUNICATION AND TRANSITION OF CARE IN ANTIMICROBIAL STEWARDSHIP



#### HEALTHCARE FACILITY TRANSFER FORM

Affix patient labels here.

Use this form for all transfers to an admitting healthcare facility.

Patient Name (Last,	, First):				
Date of Birth:	MRN	Ŀ	Transfer Date:		
Receiving Facility N	ame:		<u> </u>		
Contact Name:			Contact Phone:		
Sending Facility Nar	me:				
Contact Name:			Contact Phone:		
RECAUTIONS					
Patient currently or  Yes No	n precautions?	If yes, check all t	hat apply: Contact Droplet	☐ Enhanced	Standard*
Personal protective	equipment (PPE) to	o consider at receivin	g facility*:		
T			$\bigcirc$	<b>E</b>	<b>7</b>
□ Gloves	☐ Gown	☐ Mask	☐ N95/PAPR	☐ Eye Pro	otection
Patient has multidr  Yes (record orga	e copy of lab result ug-resistant organi nism(s), specimen:	s with organism ID ar ism (MDRO) or other source, collection dat	d antimicrobial suscept lab results requiring p e)	recautions?	
		0	refer or emposition in mile	<del>-</del>	
	Organism		Carbapenemase (if applicable)**	Source	Date
☐ Candida auris ( <b>C.</b>			(if applicable)**	Source	Date
☐ Clostridiodes diffi	auris) icile (C. diff)			Source	Date
☐ Clostridiodes diffi ☐ Acinetobacter, m	auris) icile (C. diff) ultidrug-resistant (			Source	Date
☐ Clostridiodes diffi ☐ Acinetobacter, m ☐ Carbapenem-resi	ouris) icile (C. diff) sultidrug-resistant ( istant Enterobacter	rales (CRE**)	(if applicable)**	Source	Date
☐ Clostridiodes diffi ☐ Acinetobacter, m ☐ Carbapenem-resi ☐ Pseudomonas ae	auris) icile (C. diff) ultidrug-resistant ( istant Enterobacter ruginosa, multidru	rales (CRE**) g-resistant (e.g., CRP/	(if applicable)**	Source	Date
☐ Acinetobacter, m ☐ Carbapenem-resi ☐ Pseudomonas ae ☐ Extended-spectru	auris) icile (C. diff) ultidrug-resistant ( istant Enterobacter ruginosa, multidru um beta-lactamase	rales (CRE**) g-resistant (e.g., CRPA (ESBL)-producer	(if applicable)**	Source	Date
☐ Clostridiodes diffi ☐ Acinetobacter, m ☐ Carbapenem-resi ☐ Pseudomonas ae ☐ Extended-spectru ☐ Methicillin-resist	auris) icile (C. diff) ultidrug-resistant ( istant Enterobacter ruginosa, multidru um beta-lactamase ant Staphylococcus	ales (CRE**) g-resistant (e.g., CRPA (ESBL)-producer aureus (MRSA)	(if applicable)**	Source	Date
☐ Clostridiodes diffi ☐ Acinetobacter, m ☐ Carbapenem-resi ☐ Pseudomonas ae ☐ Extended-spectru ☐ Methicillin-resist ☐ Vancomycin-resis	auris) icile (C. diff) ultidrug-resistant ( istant Enterobacter ruginosa, multidru um beta-lactamase ant Staphylococcus stant Enterococcus	ales (CRE**) g-resistant (e.g., CRP/ (ESBL)-producer gureus (MRSA) (VRE)	(if applicable)**	Source	Date
☐ Clostridiodes diffi ☐ Acinetobacter, m ☐ Carbapenem-resi ☐ Pseudomonas ae ☐ Extended-spectru ☐ Methicillin-resist ☐ Vancomycin-resis	auris) icile (C. diff) ultidrug-resistant ( istant Enterobacter ruginosa, multidru um beta-lactamase ant Staphylococcus stant Enterococcus	ales (CRE**) g-resistant (e.g., CRPA (ESBL)-producer aureus (MRSA)	(if applicable)**	Source	Date
☐ Clostridiodes diffi ☐ Acinetobacter, m ☐ Carbapenem-resi ☐ Pseudomonas ae ☐ Extended-spectru ☐ Methicillin-resist ☐ Vancomycin-resis ☐ No organism ider	ouris) icile (C. diff) ultidrug-resistant ( istant Enterobacter ruginosa, multidru um beta-lactamase ant Staphylococcus stant Enterococcus ntified (e.g., molecu	ales (CRE**) g-resistant (e.g., CRPA (ESBL)-producer aureus (MRSA) (VRE) ular screening test**)	(if applicable)**	Source	Date

					Affix patient		
					labels here.		
CLINICAL STATUS							
Patient has any of the	following s	vmptoms or cl	inical status?				
□ Yes □ No		,,					
Marca shook all that are	anath ann						
If yes, check all that cur Cough/uncontrolled		-	□ Total dependence for □ Rash consistent with				
☐ Vomiting	respiratory	y secretions	(e.g., vesicular)	n an infectious	process		
☐ Acute diarrhea or inc	ontinent s	tool 5	☐ Draining wounds §				
☐ Incontinent of urine			☐ Other uncontained	bodily fluid / d	rainage		
ANTIBIOTICS/ANTIFUNG							
Patient is currently on	antibiotics	/systemic anti	fungals?				
☐ Yes ☐ No							
If yes, specify:		$\overline{}$					
Antibiotic/Antifungal	Dose	Frequency	Indication	Start Date	Stop Date		
DEVICES 5							
Patient currently has a	ny of the f	ollowing devic	es?				
☐ Yes ☐ No							
If yes, check all that cur	rently app	ly:	☐ Wound VAC				
☐ Central line/PICC, Da	ite inserted	d:	□ Tracheostomy	☐ Tracheostomy			
☐ Hemodialysis cathete				☐ Urinary catheter, Date inserted:			
☐ Fecal management s			☐ Suprapubic catheter				
☐ Percutaneous gastro	stomy fee	ding tube	☐ Mechanical ventila	ition			
IMMUNIZATION STATUS	5						
		e.g., Pneumoci	occal, Influenza, COVID-	19) in the past	12 months?		
(Attach immunization			,,	.,			
☐ Yes (specify below)	□ No						
V	accine			Date(s)			
<u>`</u>	accine			Date(s)			

§ Risk factors for MDRO transmission per <u>Enhanced Standard Precautions</u> (PDF) (www.cdph.ca.gov/Programs/CHCQ/LCP/CDPH%20Document%20Library/AFL-19-22.pdf)

<sup>\*\*</sup> Note specific carbapenemase(s) (e.g., NDM, KPC, OXA-23) if known

ANTIBIOTICS/ANTIFUNGALS							
Patient is currently on	antibiotics	/systemic anti	fungals?				
☐ Yes ☐ No							
If yes, specify:							
Antibiotic/Antifungal	Dose	Frequency	Indication	Start Date	Stop Date		
	Ĩ						



#### **Barriers to Interfacility Transfer Communication**



### Research in Social and Administrative Pharmacy



Volume 15, Issue 4, April 2019, Pages 366-369

Inter-facility communication barriers delay resolving medication discrepancies during transitions of care

Mark E. Patterson <sup>a</sup> ∠ ⋈, Janice B. Foust <sup>b</sup>, Sandra Bollinger <sup>c</sup>, Chandler Coleman <sup>d</sup>, Diepngan Nguyen <sup>d</sup>

Show more V

+ Add to Mendeley 🚓 Share 🥦 Cite

https://doi.org/10.1016/j.sapharm.2018.05.124 >

Get rights and content ≥



## Poll Question 1 Which barriers have you experienced when a resident is transferred to your facility? Select all that apply.

- Relying on external provider/facility on accurate information that is often delayed (e.g., cultures, lab results)
- Prescribing data between your facility and the external facility not having consistent information
- Not having a standardized communication practice
- Other (Share details in the chat)



#### **Interfacility Transfer Communication Protocol**



Infection Control & Hospital Epidemiology

Article contents

Abstract

References

Interfacility transfer communication of multidrugresistant organism colonization or infection status: Practices and barriers in the acute-care setting

Part of: SHEA Research Network Collection

Published online by Cambridge University Press: 16 April 2021

Katherine D. Ellingson, Brie N. Noble, Genevieve L. Buser, Graham M. Snyder,
Jessina C. McGregor, Clare Rock, Teena Chopra, Lona Mody, Jon P. Furuno D and
SHEA Research Committee

Show author details 

Article Supplementary materials Metrics

Get access

Article Share

Article Share



## Poll Question 2 Does your facility have an interfacility transfer communication protocol in place? Select one.

- a) Yes
- b) No
- c) No, but one is being developed
- d) I am not sure



# Poll Question 3 Who receives information at your facility for interfacility transfer communication when a resident is admitted? Select all that apply.

U	D	ired	ctor	of	N	ur	S	in	ıg
---	---	------	------	----	---	----	---	----	----

- ☐ Charge Nurse
- ☐ Infection Preventionist
- ☐ Nurse caring for resident
- ☐ Other (Share details in the chat)



## Poll Question 4 Who provides information at your facility to another facility when a resident is transferred out? Select all that apply.

- ☐ Director of Nursing
- ☐ Charge Nurse
- ☐ Infection Preventionist
- ☐ Nurse caring for resident
- ☐ Other (Share details in the chat)



## Poll Question 5 When do you involve your LHD? Select all that apply.

- ☐ When a resident with MDRO is being admitted
- ☐ When a resident with MDRO is being transferred
- ☐ When there is an outbreak of an MDRO
- ☐ Other (Share details in the chat)



#### ► Improving Communication From Hospital to Skilled Nursing Facility Through Standardized Hand-Off: A Quality Improvement Project



When hand-off
communication is inadequate,
delayed patient care and
medication administration
occur, resulting in threats to
patient safety.




The application of theory, combined with the project leader and SNF management team's commitment and support, played an essential role in achieving the desired results of the quality improvement project.



Hand-off tool content should be specific to the needs of the SNF.

#### Percentage of Medications Administered Late



Use of the communication tool was associated with a reduction in the percentage of medications administered late by 52.9% for controlled medications and 77.8% for IV antibiotics.

Baluyot, A., McNeill, C., & Wiers, S. Improving Communication From Hospital to Skilled Nursing Facility Through Standardized Hand-Off: A Quality Improvement Project . *Patient Safety*, 4(4), 18–25. https://doi.org/10.33940/med/2022.12.2



Figure 1. Standardized Hand-Off Tool Utilized During Implementation

Date: Patient's Room No.:
Mental Status: ☐ Alert ☐ Not alert ☐ Oriented ☐ Disoriented
Diagnosis:
Allergies:
Isolation: ☐ Contact ☐ Airborne ☐ Droplet
Functional Status/Mobility: ☐ Independent ☐ Assist x1 ☐ Assist x2 ☐ Full mechanical lift ☐ Sit-to-stand lift
Diet: Texture: Liquids:
Tube feeding: Formula Rate Water Flush rate □ PEG □ JPEG □ NG
□TPN
Take medications: ☐ Whole ☐ With applesauce/pudding ☐ Crushed
Controlled Medication order/s:
☐ Coming in with prescription/s ☐ Need prescriptions
Date & Time prescription/s were written/called in:



#### **HEALTHCARE-ASSOCIATED INFECTIONS PROGRAM**

IV antibiotics order/s:							
☐ Coming in with prescription/s ☐ Need prescriptions							
Date & Time IV order sent to pharmacy:							
Equipment/Specific Needs:							
☐ IV/PICC line/Midline: Site ☐ Pacemaker ☐ CPAP/Bi-PAP ☐ Oxygen ☐ Trach							
☐ Lifevest ☐ Internal defibrillator ☐ Other							
☐ Foley Catheter ☐ Suprapubic ☐ Colostomy ☐ Urostomy							
☐ Wound vac: Site							
☐ External fixator ☐ Sling ☐ Cast ☐ Brace ☐ Amputation: Site Weight bearing							
status							
☐ Drain tube ☐ Chest tube Site							
☐ Peritoneal Dialysis ☐ Chemo ☐ Radiation ☐ Hemodialysis							
Sched/TimeTransportationvia ☐ Stretcher ☐ Wheelchair							
Need set up? Yes No							
Vital Signs: Time Taken Wt Ht BP RR Pulse ox on							
HR T Blood Sugar							
Completed by (Nurse's Initials): Date/Time:							




#### **Poll Question 6**

Do you use a standardized form for obtaining patient/resident == care information during transitions of care? Select one.

- ☐ Yes, always
- ☐ Yes, sometimes
- ☐ Other (Share details in the chat)







#### MOMENT 1

#### DOES MY PATIENT HAVE AN INFECTION THAT REQUIRES ANTIBIOTICS?

1. Doe	Yes	O No			
2. Wha	at are the signs/symptoms? (Check all that ap	ply)			
	Fever Increased oxygen requirements Increased respiratory rate Cough Painful urination		Wound with gross pus or drain Red, hot, or swollen skin Confusion Sleepiness Diarrhea	nage	
	New/worse incontinence		Lack of cooperation with staff		
	re supportive measures attempted?			Yes	O No
	Pain medications Reassurance Medication review Oral hydration		Wound care Nebulizer treatment Other		

#### MOMENT 2

#### HAVE I ORDERED APPROPRIATE CULTURES BEFORE STARTING ANTIBIOTICS? WHAT EMPIRIC THERAPY SHOULD I INITIATE?

5. Were antibiotics started?		Yes	O No				
	(If YES, keep going.)	(If NO, skip to question 11.)					
6. What is the role of the prescriber? Hospital provider							
Long-term care provider							
Emergency department provider							
Specialist not at hospital or em	ergency department (i.e.,	output clinic provider)					
Other							
7. Antibiotic regimen and indication:							
Antibiotic:							
Indication:							
8. Were appropriate cultures ordered by	pefore antibiotics were sta	rted?	O No				

#### MOMENT 3



#### WHAT DURATION OF ANTIBIOTIC THERAPY IS NEEDED FOR RESIDENT'S DIAGNOSIS?

9. Has a planned duration been documented in the medical record?





(If YES, keep going.) (If NO, skip to question 11.)

10. Is the planned duration consistent with local guidelines?
(See general recommendations for treatment durations below.)

DISEASE PROCESS	DURATION OF THERAPY
Uncomplicated cystitis	3–5 days, depending on antibiotic
Complicated urinary tract infection/ pyelonephritis	7–14 days, depending on response to therapy
Lower respiratory tract infection	5–7 days
Skin and soft tissue infections	5 days

QUESTIONS 11–14 SHOULD BE ANSWERED FOR PATIENTS ON ANTIBIOTICS > 24 HOURS, IN ADDITION TO QUESTIONS ON THE LAST PAGES.

#### **MOMENT 4**

A DAY OR MORE HAS PASSED. CAN WE STOP ANTIBIOTICS? CAN WE NARROW THERAPY?

11. Are antibiotics still needed?	Yes	O No
12. If antibiotics are not needed, will you stop them today?	Yes	O No
13. If antibiotics are still needed, can you narrow therapy?	Yes	O No
14. If antibiotics are still needed, can you switch from intravenous to oral?	O Yes	O No



#### **GUEST SPEAKERS**



## **Introduction: San Mateo Medical Center**

- Grace Hassid
  - MD Infection Control Officer,
     SMMC Antibiotic Stewardship (AS) Committee



## San Mateo Med Center (SMMC) Has 2 SNFs: Burlingame (281 beds) & 1A (32 beds) adjacent to Acute Care County Hospital





LTACH-vSNF Workgroup Joint Workshop
Antimicrobial Prescribing and Transitions of Care
Communication
Wednesday June 14<sup>th</sup>, 2023



Grace Hassid, MD Infection Control Officer, SMMC Antibiotic Stewardship (AS) Committee



## SMMC SNFs (1A & Burlingame) Have Met Quarterly for Antibiotic Stewardship (AS) SNF Meetings includes Infection Control since April 2016



#### **Objectives**

- 1. Describe the components of, and when to use SBAR:
  - Situation
  - Background
  - Assessment
  - Recommendation
- Implement SBAR to improve communication between nursing staff and providers
- Recognize that SBAR can support the role of nurses as advocates for antibiotic stewardship

10

 MDRO & Antibiotic Use Consistent With McGeer Criteria at AS SNF Meetings

**IHI SBAR Tool** 



#### SBAR: Improving Communication in a Brief and Timely Manner

- Situation
  - State who you are calling about and why
- Background
  - State briefly what you know about the history and the current status
- Assessment
  - State what you think the problem is and how severe it is
- Recommendation
  - State what you think needs to happen for the patient and also suggest a time frame

Case 2: Fred Bollinger – Take 2

- Situation: Hello, I am calling about Mr. Bollinger in room 332. The lab
  just called to notify me that he has a resistant organism in his urine.
- Background: He is an 83 year old man with Parkinson's disease. He
  does not have a urinary catheter. He is not on antibiotics, and no one
  can recall why the urine culture was sent.
- Assessment: He has no signs or symptoms of a urinary tract infection; his vital signs are stable and he is clinically at his baseline.
- Recommendation: I think we should continue to carefully observe him. I placed him on isolation precautions. I don't see a need to start him on antibiotics at this time.



26



#### Burlingame Skilled Nursing ANTIBIOGRAM ANNUAL 2021

Burlingame SNF
has more
urinary MDROs
than SMMC
Hospital &
Clinics

	Proteus mirabilis	Klebsiella oxytoca	Klebsiella pneumoniae	Klebsiella pneumoniae	Pseudomonas aeruginosa	Escherichia coli	Escherichia coli	Stetrophomonas maltophili:	Streptococcus agalactiae	
# OF SPECIMENS	7	1	1	1	2	5	2	1	1	l
				ESBL			ESBL			l
AMIKACIN	0	0	0	0	0	0	0			l
AMPICILLIN	71	0	0	0		60	0		100	l
CEFTAZIDINE	100	100	100	0	100	100	0			l
CEFTRIAXONE	100	100	100	0		100	0			l
CIPROFLOXACIN	71	100	100	100	100	80	50			l
GENTAMICIN	100	100	100	100	100	100	100			l
IMPINEM		100	100	100	100	100	100			l
LEVOFLOXACIN	86	100	100	100		80	50	100	100	l
NITROFURANTOIN	0	100	100	100		100	100			l
PIP/TAZO	100	100	100	100	100	100	100			l
TRIMETH/SULFA	29	100	100	100		100	50	100		l
CEFAZOLIN	100	100	100	0		80	50			l
CEFOXITIN	86	100	100	0		80	0			l
CEFEPIME	100	100	100	100	100	100	50			l
ERTAPENEM	100	100	100	100		100	100			l
TIGECYCLINE	0	0	0	0		0	0		100	l
CLINDAMYCIN									0	l
ERYTHROMYCIN										l
OXACILLIN										l
TETRACYCLINE									0	l
VANCOMYCIN									100	l
BENZYLPENICILLIN										1
MOXIFLOXACIN									100	1
LINEZOLID									100	l
RIFAMPICIN										1
QUINU/DALFO									100	l
COLISTIN										L

## June-Dec 2021 Proteus mirabilis from urine main organism cultured

#### 1A Antibiotic Stewardship Analysis

Aug, Sept, Oct 2022

	QAPI
PROBLEM	McGeer ATB CRITERIA NOT MET 25% (2/8 ATB Starts did not meet Criteria)
ROOT CAUSE ANALYSIS	All antibiotics prescribed during the month of Aug, Sept, Oct meet the criteria of McGeers except:  Aug: Wound – 1 post skin graft. Did not meet Mcgeers criteria. No symptoms  Sept: UTI – 1 Pt c/o frequent urination, Urine CX mixed flora. Did not meet Mcgeers  Criteria Oct: - None
GOAL	Goal of 10% ATB Criteria Not MET  Note: Goal of 100% MD Notification for ATB MET
IMPROVEMENT PLAN	<ul> <li>Continue to participate in quarterly ASP Meeting - ONGOING</li> <li>Provide good pericare before urine collection.</li> <li>Continue providing feedback to MD</li> <li>Patients referred to ID for consult as needed</li> </ul>
MEASURE	Next ASP



#### **ANTIBIOTIC STEWARDSHIP PROGRAM**

#### FINDINGS AND ACTION PLAN – QUARTERLY REVIEW

Problems	ATB CRITERIA NOT MET 10%
Root Causes	2 ATB criteria not met McGeers criteria and fall out case described:  July: Blood –2, UTI – 1, Skin – 1, LRI – 1  Aug: Skin – 7, UTI – 2, URI – 1  Sep: UTI – 6, Skin – 1, Other – 2
Goals	<ul> <li>Less than or equal to 10% ATB criteria was NOT MET for JULY and SEP 2022.</li> <li>Less than or equal to 10% ATB criteria was MET for AUG 2022.</li> </ul>
Improvement Plans	<ul> <li>Continue to participate in quarterly Antibiotic Stewardship/ Infection Control meetings at San Mateo Medical Center</li> <li>Continue providing ASP Reports – Physician's Prescribing Patterns Log to clinicians and provide feedback monthly or quarterly</li> </ul>
Measures	Goal(s) will be measured by the next Quality Assurance and Performance Improvement (QAPI) committee meeting.

#### Multidrug Resistant Organisms

- Rising numbers in US, California and around the world
- Antibiotic Stewardship and Environmental Controls are crucial to prevent their development and spread
- Extended Standard Precautions (ESP) are helpful in the SNF setting
- History of being hospitalized or receiving medical care abroad increases risk
- Organisms may not be apparent upon admission but appear after pressure from antibiotic use



#### Antibiotic Stewardship Principles

- Right Drug
- Right bug
- Right amount of time
- Communication with patient to follow the medical plan, instructions to not stop early to use antibiotic "in the future" or share with family members or friends
- Communication with other facility in case of transfer, use of interfacility CDPH form and phone call to inform of needed infection control parameters



## SAN MATEO SAN MATEO MEDICAL CENTER

#### **Education Tools**

- Daily, weekly or biweekly huddles between Infection Control and SNF Staff depending upon need
- SNF Staff attend Infection Control Meetings for broad overview
- Use of TEAMS texting to request case reviews for possible transfers from Acute Care to SNF setting
- Direct Observations of Hand Hygiene and PPE use daily in the SNF setting by both Charge RN and "secret shoppers" when available
- Bivalent Vaccine Campaign to increase staff acceptance
- Ongoing Education of patients to perform hand hygiene regularly, helps to decrease # resistant bacteria selected out from antibiotic use

#### Pearls

- Create a culture of safety and inclusion to protect our patients, our staff and our families
- Administration, nursing leadership and all staff must be aligned in the importance of Antibiotic Stewardship to both heal patients and decrease the threat of untreatable infections
- Work closely with Environmental Services as essential members of the team for maximal cleanliness and safety
- Everyone must educate at every opportunity on this topic, our future depends upon it!



### Antibiotic Stewardship Committees: SMMC Hospital/Clinics & Skilled Nursing Facilities (Burlingame & 1A SNFs)

**Niloofar Zabihi, Pharm D (Pharmacy)** 

Victor Armendariz, Pharm D (Pharmacy)

Wan Chen, Nurse Analyst (Quality/RN Informacist)

Michele Medrano, R.N. (Infection Control) Ambulatory

**RNs Involved in AS** 

**Grace Hassid, M.D. (Infection Control Officer)** 

Jen Obina, R.N. (Infection Control)

**Kristine Peralta, R.N. (Infection Control)** 

**Chad Below (Lab Manager)** 

Suja Georgie, M.D. (Hospitalist)

**Kyaw Myint, M.D. (Hospitalist)** 

Cecil Agdipa, R.N. (IT)

Lilly Jensen, M.D. (SNF Medical Director/ Hospitalist)

Jessica Chu (ED)

Amanda Hing Hernandez, M.D. (Ambulatory)

Roberta Larcina, R.N. (Nursing)

Raquel Villarina, R.N. (SNF Nurse Educator)

**David Yang** (Infection Control, Burlingame SNF)

Vivian Levy, M.D. (ID)





**QUESTIONS?** 

## **Introduction:** Hoag Hospital

- Philip Robinson, MD
  - Medical Director of Infection Prevention and Hospital Epidemiology
     Principal Investigator of Infectious Disease Research
- Jason Yamaki PharmD, PhD
  - Infectious Diseases Pharmacist




## Hoag + LTC/SNF Collaborative Partnership

Dr. Philip Robinson MD

Medical Director of Infection Prevention and Hospital Epidemiology Principal Investigator of Infectious Disease Research

Jason Yamaki PharmD, PhD
Infectious Diseases Pharmacist

Disclosure: Dr. Robinson is a founder, and Dr. Yamaki is lead pharmacist for Expert Stewardship, Inc.



## Approach



Top ~20 SNFs with patient exchanges with Hoag Identified



Formal letter requesting partnership sent (10 responses)



Requested data on Infection Prevention, patient days, ABX use

#### Observations

- 65% of LTC residents have an MDRO
- Most common reasons for antibiotic in LTC:
  - Legacy antibiotics from the hospital (can be expensive)
  - New Pneumonia/UTI (many do not meet criteria)
  - Antibiotic courses are too long
- 30-50% of antibiotics may not be appropriate
- Most commonly used antibiotic class fluoroquinolones
- Resistance to fluoroquinolones was very high 40-80%
- Knowledge gap related to the side effects of fluoroquinolones (FDA) in addition to C. diff risk
- No guidelines for antibiotic usage

## Accomplishments

#### Interventions


- Antibiotic Use Guidelines
  - Choice
  - Duration
- Antibiotic Therapeutic interchanges
- Education

#### **Outcomes**

- Reduced inappropriate antibiotic use and durations
- Reduced costs
- Reduced Cdiff



Ceftriaxone Guidelines
Quinolone Education
Length of therapy
education
Therapeutic substitutions\*




## Additional Services Provided


- SNF Quarterly meetings data shared on readmissions, ABX use trending, etc
- Availability of Hoag IP Medical Director for questions
- Hoag Microlab providing C & S
- Annual antibiogram generation

## GROUP DISCUSSION: HAVE YOU ESTABLISHED OR IMPROVED YOUR PROCESS FOR INTERFACILITY TRANSFER COMMUNICATION?



#### **ZOOM ANNOTATION FEATURE**







## Question 1 Who are your partners for interfacility communication?



# Question 2 How have you leveraged partnerships in interfacility communications? (e.g. How do you get prescribing information? Who do you contact?)



#### **Question 3**

What are *challenges* when gathering antimicrobial prescribing information or microbiology results? (e.g., with initial information gathering, follow-up)



### Question 4

What are *solutions* when gathering antimicrobial prescribing information or microbiology results? (e.g., with initial information gathering, follow-up)



Question 5
What is one thing you learned today that you can take back to your facility? (e.g., share an 'aha moment')



#### **Next Steps**

☐ Fill out the **course evaluation** (required for CEU)

#### For LTACH:

- July 11, 2023 Cohort 3: Conducting Interim Analysis and Adjusting Using PDSA
- August 8, 2023 Final All Cohort Meeting

#### For vSNF:

- □ Next meeting on Wednesday, September 13, 2023: Quality Improvement Project Updates Part 3
- ☐ Continue to **check in monthly** with your HAI Program IP and continue **planning and implementing your QI project**
- ☐ Access resources on <u>vSNF webpage</u>
  (www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/vSNF.aspx)

#### **Questions?**

LTACH Contacts

Jane.Kriengkauykiat@cdph.ca.gov

Becca.Czerny@cdph.ca.gov

vSNF Contact Erin.Garcia@cdph.ca.gov

